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Abstract 
Background:  Different countries have different preferences regarding health, and there are different value sets for 
popular preference-based measures across different countries. However, the cost of collecting data to generate 
country-specific value sets can be prohibitive for countries with smaller population size or low and middle income 
countries (LMIC). This paper explores whether existing preference weights could be modelled alongside a small 
own country valuation study to generate representative estimates. This is explored using a case study modelling UK 
data alongside smaller US samples to generate US estimates. Methods: We analyze EQ-5D valuation data derived 
from representative samples of the US and UK populations using time trade-off to value 42 health states. A 
nonparametric Bayesian model was applied to estimate a US value set using the full UK dataset and subsets of the 
US dataset for 10, 15, 20 and 25 health states. Estimates are compared to a US value set estimated using US values 
alone using mean predictions and root mean square error. Results: The results suggest that using US data elicited for 
20 health states alongside the existing UK data produces similar predicted mean valuations and RMSE as the US 
value set, while 25 health states produces the exact features. Conclusions: The promising results suggest that 
existing preference data could be combined with a small valuation study in a new country to generate preference 
weights, making own country value sets more achievable for LMIC. Further research is encouraged. 
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Valuation of preference-based measures: Can existing preference data be used to select a 
smaller sample of health states? 
 
Abstract 
 
Background:  Different countries have different preferences regarding health, and there are different value sets for 
popular preference-based measures across different countries. However, the cost of collecting data to generate 
country-specific value sets can be prohibitive for countries with smaller population size or low and middle income 
countries (LMIC). This paper explores whether existing preference weights could be modelled alongside a small 
own country valuation study to generate representative estimates. This is explored using a case study modelling UK 
data alongside smaller US samples to generate US estimates. Methods: We analyze EQ-5D valuation data derived 
from representative samples of the US and UK populations using time trade-off to value 42 health states. A 
nonparametric Bayesian model was applied to estimate a US value set using the full UK dataset and subsets of the 
US dataset for 10, 15, 20 and 25 health states. Estimates are compared to a US value set estimated using US values 
alone using mean predictions and root mean square error. Results: The results suggest that using US data elicited for 
20 health states alongside the existing UK data produces similar predicted mean valuations and RMSE as the US 
value set, while 25 health states produces the exact features. Conclusions: The promising results suggest that 
existing preference data could be combined with a small valuation study in a new country to generate preference 
weights, making own country value sets more achievable for LMIC. Further research is encouraged. 
 
Keywords: preference-based health measures; nonparametric Bayesian methods; time trade-off; EQ-5D. 
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1. Introduction 
 
Health resource allocation is becoming increasingly important in an economic climate of increasing demands on 
healthcare systems with constrained budgets. Economic evaluation using cost-utility analysis is becoming a widely 
popular technique internationally to inform resource allocation decisions. Cost-utility analysis measures benefits 
using Quality Adjusted Life Years (QALYs), a commonly used measure that multiplies a quality adjustment for 
health by the duration of that state of health [11]. The quality adjustment weight is generated using utility values 
where 1 represents perfect health and 0 represents dead, and is most often generated using an existing preference-
based measure. A preference-based measure consists of a classification system used to describe health (patients 
report their own health and this is assigned to a health state using a classification system) and a value set that 
generates a utility value for every health state defined by the classification system. 
 
Currently, a number of preference-based measures of health-related quality of life (HRQoL) are available, including 
EQ-5D [1], HUI2 and 3 [2, 3], AQoL [4], QWB [5], and SF-6D [6], though there are an increasing number of 
condition-specific measures available [7]. The EQ-5D has become a popular measure of HRQoL and there are many 
different value sets available for two reasons. First, different countries can have different preferences. Different 
countries have different population compositions, different types of work, different cultures, and these can all impact 
on the relative values given to different dimensions of health (for example, self-care and anxiety/depression) as well 
as where on the 1-0 full health-dead scale each health state lies. The ordering of health states can vary across 
countries, as well as the position on the scale in relation to dead.  Although Badia et al. [8] reported quite small and 
unimportant differences in EQ-5D valuations between UK, US and Spain, it is shown in Johnson et al. [9] that 
differences between the US and UK were potentially important. Second, international agencies that review cost-
utility analyses in order to inform resource allocation decisions typically prefer QALYs to be generated using their 
own country value set (see Rowen et al. [10] for an overview). This is related to the first reason, as if different 
FRXQWULHV KDYH GLIIHUHQW SUHIHUHQFHV LW LV LPSRUWDQW WR WDNH LQWR DFFRXQW WKH FRXQWU\¶V RZQ FLWL]HQV YLHZV ZKHQ
making resource allocation decisions. However, the cost of collecting data to generate country-specific value sets 
can be prohibitive for countries with smaller population size or low and middle income countries (LMIC). For 
example, if valuation data is collected via face-to-face interview this can be costly and time consuming and the 
number of interviews would be in the hundreds. Although valuation data can be collected online, making the data 
collection quicker and cheaper, this is not feasible for all countries. For some LMIC the use of an online survey may 
be impractical and may not achieve a representative sample of the general population by sociodemographic 
characteristics. In addition, understanding of valuation tasks cannot be monitored in an online environment which is 
a disadvantage for data collection in countries where valuation tasks have not been undertaken previously. This can 
mean that for these countries that value sets of alternative countries are used instead to generate QALYs, such as UK 
RU86YDOXHV\HW WKHVHYDOXHVPD\QRWEHUHSUHVHQWDWLYHRI WKHFRXQWU\¶VRZQ citizens, and this could potentially 
impact on the validity of the resource allocation decisions made. 
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There is now an increasing number of datasets of preference data, where preferences have been elicited for the same 
measure for different countries. In Kharroubi et al [11] a nonparametric Bayesian method is used to model the 
differences in EQ-5D valuations between the US and UK as an alternative approach to the parametric random-
effects model of Johnson et al. [9]. Recently, this model has also been applied to the joint UK-Hong Kong and UK-
Japan SF-6D data set ([12], [13]).  
 
Such a model offers a major added advantage as it permits the utilization of the already existing results of one 
country to improve those of another, and as such generated utility estimates of the second country will be more 
SUHFLVHWKDQZRXOGKDYHEHHQWKHFDVHLIWKDWFRXQWU\¶VGDWDZDVFROOHFWHGDQGDQDO\]HGRQLWVRZQ Such an analysis 
(drawing extra information from country 1) may allow a reduction in the sample size in country 2 in order to attain 
the same precision as achieved with a complete valuations in that country.  
 
The aim of the paper is to determine whether an accurate value set can be generated for a country using only a small 
sample of data collected in that country, through jointly modelling the data with data collected for another country. 
This is explored using a case study for US and UK data, where a range of subsets of the health states valued in the 
US study are modelled alongside the full UK dataset, and the estimates are compared to the estimates generated 
modelling US data alone.  
 
First the US and UK EQ-5D valuation studies as well as the datasets used here are summarised. Second the 
Bayesian non-parametric model is described and third the results are presented. Finally, the results are discussed, 
including limitations and suggestions of possible directions for future research. 
 
2. EQ-5D data set 
 
The EQ-5D is a descriptive system defined by five health dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each is assigned to three levels of health-UHODWHGSUREOHPV³QRSUREOHP´
OHYHO³PRGHUDWHRUVRPHSUREOHP´OHYHODQG³VHYHUHSUREOHP´OHYHO  Different combinations result in 
243 possible health states, which are associated with a five-digit descriptor ranging from 11111 for perfect health 
and 33333 for the worst state possible. For example, state 13232 translates into no problems in mobility, severe 
problems in self-care, moderate problems in usual activities, extreme pain or discomfort and moderate anxiety or 
depression [15]. 
 
For EQ-5D to be used as a preference-based measure of HRQoL, a single utility value is assigned to each health 
state; by convention, utility value of 1 designates full health with all the rest having values less than one.  Immediate 
death is conventionally assigned the utility zero and is considered as a baseline against the different health states that 
can possibly assume negative value had they felt worse than death. These utility indexes have been elicited from the 
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valuation survey undertaken by the Measurement and Valuation of Health (MVH) group at York, using the time 
trade off (TTO) technique [16]. A representative sample of 3395 members of the UK general population were 
interviewed in their own homes, where they were asked to value 12 health states. The valuation did not include all 
243 states defined by the EQ-5D and chose to value a sample of 42 states. Further details on this study are provided 
elsewhere [17]. 
 
The US valuation study valued an identical set of states using the same UK valuation methods. However a different 
approach was used to sample respondents, where a 4-stage clustering sampling strategy was used, that focused on 
the Hispanics and non-Hispanic blacks [18]. One further difference was that respondents were interviewed in 
English in the UK whereas in the US respondents had the choice of being interviewed in either English or Spanish. 
The UK study interviewed a sample of 3395 respondents (response rate: 64%) whereas a sample of 4048 (response 
rate 59.4%) respondents were interviewed in the US study. However, respondents were not included due to missing 
and/or inconsistent responses. This results in a total of 2997 UK respondents and 3773 US respondents. Both 
samples represented their populations in regard to sociodemographic characteristics [17, 18].     
 
Both studies elicited TTO valuations for the 42 EQ-5D health states [17-18].  Briefly, respondents were first asked 
whether an impaired health state is better or worse than immediate death. For health states regarded as better than 
dead, respondents were asked to choose between living full health for x, years (x RU  \HDUV VSHQW LQ WKH
impaired health state. For states regarded as worse than being dead, respondents were provided the choice of living 
in that state for (10-x) years. This is followed by living in perfect health for x years (x<10) or immediate death. The 
valuation scores were then transformed using the equation x/10, if states considered as better than death, and in the 
UK study -x/10, if states regarded worse than death, in order to bound them on the [-1, 1] scale [19], and in the US 
study (-x/(10-x))/-z where z is the worst value produced by -x/10, which is -39 in this case [18]. 
 
The UK and US valuations studies also differed in procedures for assigning health states (i.e. 12 states for each 
respondent). The US individuals were randomized to receive 1 of 5 groups of pre-defined health states, where 4 
groups included 33333 in addition to 2 randomly selected very mild states and 9 states randomly selected from the 
remaining 36 EQ-5D states. The 5th group included 33333 and 11 health states selected randomly from the 
remaining 41 states. In the UK, however, 41 health states (excluding 33333) were stratified into 4 classes according 
to severity of problems, where each individual was randomly assigned 2 very mild, 3 mild, 3 moderate, and 3 severe 
states, plus 33333. Further details on the UK and US studies have been reported elsewhere [17-18].   
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3. Modelling  
 
The modelling approach is described in Kharroubi et al. [11], where a nonparametric Bayesian model was used to 
model the differences between the US and UK EQ-5D health state valuations, providing an alternative approach to 
the conventional parametric model. Using the full US and UK data, Kharroubi et al. [11] found potentially important 
differences between the US and UK valuations of EQ-5D. In particular, Kharroubi et al. [11] found that US 
individuals give bigger utility values on all of the 42 health states. Because the covariates and respondent random 
effects enter the nonparametric Bayesian model multiplicatively, the difference between the two countries was 
shown to be minor for good and moderate health states and at its major for the worst health state. In addition, there 
seemed to be a substantial interaction between nationality and gender. Kharroubi et al. [11] found that the tendency 
to give bigger utilities is stronger for females than for males in the UK, while this is not the case for the US 
respondents. Finally, Kharroubi et al. [11] showed that the US respondents are more sensitive to poor health in 
mobility and self-care, but less sensitive in the dimensions of usual activities, pain and anxiety. A detailed 
description of the analysis is provided in Kharroubi et al. [11]. 
 
In this article, we follow on from this work to examine whether the adoption of a range of sample sizes of US health 
states (10, 15, 20, 25 states), while borrowing extra evidence from the UK study, generates the same valuations as 
analyzing the full US data by itself. The model is estimated using a restricted sample of the US health states (10, 15, 
20 and 25) alongside the full UK sample. These estimates are compared to those estimated using all US data 
excluding the UK data using different prediction criterion, including predicted versus actual mean health states 
valuations, mean predicted error, root mean squared error and an out-of-sample prediction. 
 
For combined analysis, data from the US and UK studies were combined as being derived from one study with 
m=6770 respondents. For i  « jn  and  j  «m, xij is the ith health state valued by respondent j and the 
dependent variable yij is the TTO valuation given by respondent j for that health state. Finally, let tj be a vector of 
covariates for respondent j. In particular, tj includes a dummy variable to differentiate rHVSRQGHQWV¶QDWLRQDOLGHQWLW\, 
EXWLWDOVRLQFOXGHVWKHUHVSRQGHQW¶VDJHDQGVH[ 
 
Kharroubi et al. [11] model the ith valuation by respondent j as 
^ ` ijijcjjij uhy HDJ  )(1))(exp(1 ' xt ,   (1) 
where )( jh t being a vector of functions of covariates tj and Ȗ is a vector of unknown coefficients, jD  is a random 
individual effect, ijH is the usual random error, )(xcu is the base utility for the health state vector x and the 
subscript c represents the UHVSRQGHQW¶VFRXQWU\, where c =  1 if respondent j is in the US sample, and c =  0 if he/she 
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is in the UK sample..  It is perhaps easier to understand (1) by writing it in terms of disutilities ݖ௜௝ ൌ  ? െ ݕ௜௝ and ݒ௖൫ܠ௜௝൯ ൌ  ? െ ݑ௖൫ܠ௜௝൯ as ݖ௜௝ ൌ ൫ߛᇱ൫࢚௝൯ ൅ ߙ௝൯ ݒ௖൫ܠ௜௝൯ ൅ ߝ௜௝i.e. simply a multiplicative model with zero 
intercept.  Then we see that the observed disutility ݖ௜௝  is modelled as the base disutility ݒ௖൫ܠ௜௝൯for the respondent¶s 
country c, mXOWLSOLHGE\WKHUHVSRQGHQW¶VHIIect and then with random error applied. For perfect health, ݑ௖൫ܠ௜௝൯ ൌ ?ǡi.e. ݒ௖൫ܠ௜௝൯ ൌ  ?ǡand all respondents value it as such apart from the random elicitation errors ߝ௜௝. For poorer health 
states, ݒ௖൫ܠ௜௝൯ is larger and respondent covariate and random effects produce larger variations in the elicited values, 
thereby accounting for the observed JUHDWHUYDULDELOLW\LQUHVSRQGHQWV¶XWLOLWLHVIRUSRRUHUKHDOWKVWDWHV  
 
The interpretation of the base utility ݑ௖ሺܠሻ for country c is that this is the utility function for a respondent from that 
country with respondent effect ߣ௝ ൌ ൫ߛᇱ൫࢚௝൯ ൅ ߙ௝൯ ൌ  ?. A respondent with ߣ௝ > 1 will exhibit greater disutility 
and hence lower utility than the base utility for all states x. The differential is greater for states with low utility than 
for those with higher utility (and is zero for perfect health). Conversely a respondent with ߣ௝ < 1 will have higher 
utilities than the base function for all x, also with increasing differential the lower the base utility of x. This is a key 
feature of model (1) that is observed in valuation data, and is one way in which it better represents reality than that 
of previous analysis (see Kharroubi et al. [11] for more details). 
 
Kharroubi et al [11] formally assumed normal distributions for the random terms, 
Dj a ),0( 2WN   and ijH  a ),0( 2vN . 
where 2W and 2v are further parameters to be estimated.  The distribution of  ߣ௝ is then log-normal, resulting in a 
skewness that is also typically observed in valuation data. . Note that t`s are centred to ensure that they have zero 
means, and hence that the value of ߣ௝ for a typical person is 1.   
 
Kharroubi et al. [11] model the relationship between the two base utility functions through 
  )()( 00 xxx du c 0ȕP ,                          (2) 
)()()()( 101 xxx du cc 10 ȕȕPP .  (3) 
where 0P , 1P , 0ȕ  and 1ȕ  are unknown coefficients and )(xd  denotes a shift of the utility function from the 
linear regression form. The expression x0ȕc0P  in (2) expresses a prior belief that the utility function )(0 xu  for 
UK respondents will be approximately linear and additive in the various dimensions. The corresponding expression 
[8] 
 
in (3) modifies (2) with additional coefficients 1ȕ  in order to reflect dimension-specific differences between the US 
and UK [11], but notice they share the same )(xd  function.  Hence, we suppose that the utility functions for the 
two nationalities have the same basic shape but can nevertheless differ in important respects. 
 The term )(xd  is dealt with as an unknown function and so in Bayesian context it will be treated as a random 
variable.  Kharroubi et al. [11] assign independent normal distribution to )(xd  as  
)(xd a ),0( 2VN  
for all x and 
,})(exp{))(cov( 2'ddd xxbdd  ¦'(x x),   (4) 
where for d  « dx  and 'dx  are the levels of dimension d in the health states x and xc , respectively, and 
bd is a roughness parameter that controls how closely the true utility function is expected to adhere to a linear form 
in dimension d [14]. The effect of this function is to assert that if x and xc  describe very similar, their utilities will 
be almost the same, and so the preference function varies smoothly as the health state changes. The key point about 
this model is that it allows )(xd to take any values and hence the utility functions are not constrained in the way 
that they are with parametric regression models. It is in this sense that we describe our model as nonparametric, and 
we believe that this is another way in which our model is more realistic than that of previous analysis. For more 
details on this part of the model see Kharroubi et al. [14].  
 
Subsets of the US sample were selected using systematic random sampling. The sample of 10 US health states was 
chosen using systematic random sampling as follows: we first sorted the 42 US health states in increasing order, 
then, we selected one health state from the list at random. Every 4th health state from then on has been selected. The 
systematic random sampling method was adopted in order to make sure that each sampled health state is a fixed 
distance apart from those that surround it. 
 
The sampling technique of the 15 US health states is similar selecting each 3rd health state, with a randomly selected 
health state as starting point. The sampling of the 20 US health states uses the same approach, but with each 2nd 
health state selected. The sample of 25 US health states was selected as above; that is, with every other health state 
being chosen starting from the random selection (baseline). 
 
Given the overall aim of the models is to predict health state valuations, model performance is assessed using 
predictive ability, presented using plots of predicted to actual values, calculations of the mean predicted error, root 
mean squared error (RMSE) and plots of the standardised residuals. 
 
[9] 
 
4. Results 
4.1.  10 US health states 
 
Column 2 of Table 1 displays the actual mean health state utility values of the US data. Columns 3 & 4 show the 
predicted mean health state utility values and standard deviation for the US population on its own, while columns 5 
& 6 show the predicted population mean health state utility and standard deviation using the 10 health states valued 
in the US (in bold font) and UK data (which we shall referred to henceforth as US/UK). As can be seen, the 
predicted mean valuations ranged from -0.3082 (33333) to 1 (11111) for the US and from -0.3426 (33333) to 1 
(11111) for the (US/UK) population. Figure 1 presents the estimated mean valuations (pink line) for the US 
population alone and the observed (blue line) along with the yellow line reflecting the difference between both 
values. Figure 2(a) presents the corresponding plots for US/UK population. As depicted from Figure 2(a), the 
predicted valuations by employing only 10 health states from the US population, while adopting all the UK data do 
not fall in agreement with the observed US valuations. It also shows obvious fluctuations in the predicted US/UK 
valuations which in turn justifies the non-steady trend of the difference line. Additionally, the observed RMSE for 
the US population by itself is 0.0576, whereas the US/UK achieves a 0.1021, which is almost of double size.  Based 
on these results, we believe that a sample of 10 US health state is too little and hence more US states are required in 
order to get results that are in agreement with those attained with the complete US valuations. 
 
4.2 15 US health states 
 
Columns 7 & 8 of Table 1 show the estimated population mean valuations and standard deviation using the 15 
health states valued in the US/UK (in bold font) data. The predicted mean valuations varied from -0.3337 (33333) to 
1 (11111) for the (US/UK) population. Figure 2(b) presents the estimated valuations (pink line) for the US/UK 
population and the observed mean valuations of the US population (blue line), along with the difference between the 
two valuations (yellow line). In comparison with Figure 2(a), the results presented in Figure 2(b) show a little 
improvement, although there is still some fluctuations in the predicted US/UK valuations. This is also the case with 
RMSE of 0.0883 for the US/UK valuations compared to 0.0576 for the US only. This suggests that 15 US health 
state is still a small sample and hence more US states are required in order to get results that are in agreement with 
those attained with the complete US valuations. 
 
4.3 20 US health states  
 
Columns 9 & 10 of Table 1 show the estimated population mean valuations and standard deviation using the 20 
health states valued in the US/UK (in bold font) data. The predicted mean valuations varied from -0.3105 (33333) to 
1 (11111) for the (US/UK) population. Figure 2(c) represents the estimated valuations (pink line) for the US/UK 
population and the observed mean valuations of the US population (blue line) as well as the difference between the 
two valuations (yellow line). We see from Figure 2(c) that both valuations are very close for most of the 42 health 
[10] 
 
states. In comparison with Figure 1, the predicted valuations by employing only 20 health states from the US 
population, while adopting all the UK data are in good agreement with those obtained with the full US sample. 
Additionally, the observed RMSE for the US/UK is 0.0665, which is very close to the one obtained using the US 
data only (0.0576). Based on these results, we believe a sample of 20 US health states in addition to the whole UK 
data might be sufficient to get results that are in quite good agreement with those attained with the complete US 
study.  
 
4.3 25 US health states 
 
To be more cautious, we take a step further and look at 25 US health states together with the 42 UK health states. 
This is to ensure we get good answers (or even better) as those obtained with the full US study. Columns 11 & 12 in 
Table 1 show the predicted population mean valuations and standard deviation using the 25 health states valued in 
the US/UK (in bold font) data. The predicted mean valuations varied from -0.3242 (33333) to 1 (11111) for the 
(US/UK) population. Figure 2(d) represents the predicted valuations (pink line) for the US/UK population and the 
observed mean valuation of the US population (blue line). The yellow line represents their difference. We see from 
Figure 2(d) that both valuations are very close for most of the 42 health states. In comparison with Figure 1, the 
predicted valuations by employing 25 health states from the US population, while adopting all the UK data are in 
perfect agreement. Additionally, the observed RMSE for the US/UK achieves 0.0554, which is very similar to the 
one obtained using the US data only (0.0576). This implies that a sample of 25 US health states in addition to the 
whole UK data is the ideal scenario needed to adopt in order to obtain results that are in excellent agreement with 
those obtained with the full US sample. 
 
Another comparison of the two approaches is to conduct an out of sample prediction for the remaining health states 
that were included in the US valuation survey but not included in the model. Given that 25 US health states were 
used for model fitting, we make use of this model to prediction for the remaining 17 health states. Table 2 displays 
the true sample means for these 17 missing states, together with the posterior means and standard deviations for 
these means in the (US/UK) as well as the US valuations only. It is clear that both estimated value sets are close 
most of the health states. However, the predictive performance for the US/UK model is slightly better since the 
mean and variance of the standardised prediction errors are 0.275 and 0.443 respectively for US/UK versus 0.3604 
and 0.524 for the US only. Additionally, RMSE are slightly better as well, with 0.099 for the US/UK data and 
0.1055 for the US only. The better predictions may be observed because the Bayesian model is able to borrow 
strength from the UK data (as informative priors), and as such better estimation of the US population utility function 
are obtained. For visual checking, Figure 3 shows the standardised prediction errors in two Q-Q normal plots. Panel 
(a) plots the errors for estimating the 17 sample means using the US data only, while panel (b) shows the 
corresponding errors using the US/UK data. In each case the solid line represents the theoretical N (0,1) distribution. 
In theory we would expect the quantiles of the standardised predictive errors to lie roughly on the theoretical line i.e. 
have the same distribution. It is clear that the both predictions are pretty similar, though the combined analysis is 
[11] 
 
slightly better. This implies that the results obtained are in line with our hypothesis and that there is no need to adopt 
more than 25 health states from the US data to obtain the results we are seeking in health states valuations studies.  
 
5. Discussion  
 
Here we have applied a non-parametric Bayesian method to the existing US-UK EQ-5D valuations in an attempt to 
determine what size sample in the US EQ-5D health states, while also borrowing extra strength from the UK data, is 
needed in order to get answers that are as well as those attained with the full US study. We have shown that, with the 
increased number of states considered, we were able to develop a higher accuracy of the results obtained for all 
criterion used, including predicted versus actual mean health states valuations, mean predicted error, root mean 
square error and an out of sample prediction. Furthermore, we have concluded that a sample of 25 (or even 20) US 
health states as well as the whole UK data is the ideal scenario needed to adopt in order to obtain results that are in 
excellent agreement with those obtained with the full US sample, based on predictive ability of the models. This is a 
promising approach that suggests that existing preference data could be combined with a small valuation study in a 
new country to generate preference weights, making own country value sets more achievable for LMIC. 
 
The novelty of the analysis presented here was to use the pooled data when we have a large quantity of observations 
on one country and limited observations on another. In the analysis presented here we have shown that drawing 
extra information from the first country allows us to reduce the sample size in the second country, and for this to 
attain the same precision as we would obtain with a complete data in that country. This kind of analysis could be 
extremely important in countries without the same ability to conduct large evaluation studies. 
 
The nonparametric Bayesian model offers a major added advantage: In the existence of lots of observations on one 
country and limited on another, it permits the utilization of results of country 1 to improve the results of country 2, 
and as such generated utility estimates of the second country may be better than would have been the case if that 
FRXQWU\¶V GDWD was collected and analyzed on its own. This in turn would reduce the need for undertaking large 
surveys in every country using costly and more often time-consuming face to face interviews with techniques such 
as SG and TTO. To our knowledge, this concept KDVQ¶WEHHQ LQYHVWLJDWHGSURSHUO\\HWEXWFOHDUO\ LW KDVD ORWRI
potential value. Further research is underway to assess this. 
 
Limitations of this study include the use of only two datasets as a case study. Value sets can differ across countries 
both in terms of the ordering of health states due to differences in relative preferences of the dimensions, and the 
location of states on the 1-0 full health-dead scale. Different population compositions, types of work, cultures and 
languages can all have an impact, suggesting that this approach may not always produce accurate estimates. The UK 
and US populations have different population compositions, yet may be more culturally similar than, for example, 
high income and low income countries. This approach may be of most benefit where the samples that are combined 
have cultural similarities, as in the case of the UK and US. This approach could be used by LMIC to combine 
[12] 
 
resources to generate value sets for each individual country generated by combining data collected across different 
countries with cultural similarities. The accuracy of estimates may not be at an acceptable level for countries where 
there may be larger differences in their health valuations to the larger country whose data is modelled alongside. 
Further research is encouraged to examine whether this approach is appropriate using countries which have greater 
cultural differences, where relative preferences across different dimensions may differ leading to a different ordering 
of mean valuations of health states7KLVZLOOEHXVHIXOIRULQIRUPLQJXQGHUZKDWFLUFXPVWDQFHVRQHFRXQWU\¶VYDOXHV
may be qualified to be modelled alongside the country of interest to generate their value set. In addition, the location 
of dead may be a limiting factor, where even if the ordering of states is similar there may be differences in where 
these states are located on the 1-0 full health to dead scale. Further research is underway to assess this. In particular, 
ongoing research on exploring whether using the UK data might help with the design and analysis of a valuation 
study for SF-6D in Hong Kong has preliminary results that are very promising. 
 
One limitation of the approach used to select health states is that the selection was not restricted to the subsample of 
states valued by a small sample of people. In the US study there were 5 groups that each valued a different set of 
states, and hence here states could have been selected using one group alone, two groups, and then three groups. 
However, this should not impact on the results since if new data was being collected with the aim of being analysed 
using the Bayesian approach reported here, health state selection could be informed by these analyses.  
 
An additional limitation is that the approach does not explore whether the same results could have been achieved 
through keeping the same number of health states and reducing the sample size. However, it is not anticipated that 
this would impact on the results, though this can be explored in future research. Furthermore, the Bayesian non-
parametric value sets reported here differ to parametric value sets generated for the EQ-5D that are commonly used 
to generate QALYs [17, 18], though it is possible that a similar approach could be used to generate parametric 
estimates.  
 
Furthermore, as many international agencies recommend the use of country own value sets to generate QALYs, it is 
XQFOHDUZKHWKHUDYDOXHVHWJHQHUDWHGXVLQJRZQFRXQWU\GDWDPRGHOOHGDORQJVLGHDQRWKHUFRXQWU\¶VGDWDVHWZRXOG
be acceptable. However, this may not be a concern if the estimates are accurate and the ordering of health states and 
location on the 1-0 full health-dead scale is similar to those achieved using a large scale valuation study. 
 
In conclusion, the simple idea of pooling the US and UK data proves to be significant in terms of reducing the need 
for EQ-5D to be valued separately in each country. The model used in this article could be applied to other 
preference-based measures such as SF-6D, 15D and HUI-II, in addition to disease-specific measures where this 
approach could be particularly promising. Further research is underway to apply this to SF-6D.  
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Figure 1: Actual (blue line) and predicted (pink line) estimates  
and their difference (yellow line) for US health states only. 
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Figure 2: Actual (blue line) and predicted (pink line) estimates and their difference (yellow line) for: (a) 10 US & 
UK health states; (b) 15 US & UK health states; (c) 20 US & UK health states; (d) 25 US & UK health states. 
 
(a) (b) 
(c) (d) 
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Figure 3b: Standardized residuals Q-Q plot for the 
US/UK data (25 US health states) 
Figure 3a: Standardized residuals Q-Q plot for the 
US data only 
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Table 1: Posterior estimates for various sampled US health states, in addition to the whole US data 
  
US data ONLY 10 US & UK data 15 US & UK data 20 US & UK data 25 US & UK data 
HS Observed Predicted Predicted Predicted Predicted Predicted Predicted Predicted Predicted Predicted Predicted 
   Mean Mean STD Mean STD Mean STD Mean STD Mean STD 
11111 1 1 0 1 0 1 0 1 0 1 0 
11112 0.8385 0.8199 0.0089 0.8403 0.0208 0.9089 0.0145 0.8714 0.0128 0.8442 0.0070 
11113 0.5422 0.4848 0.0139 0.3412 0.0299 0.5628 0.0210 0.4730 0.0124 0.4846 0.0102 
11121 0.8632 0.8490 0.0102 0.9462 0.0167 0.8680 0.0090 0.9242 0.0133 0.8681 0.0079 
11122 0.7693 0.7386 0.0125 0.7580 0.0119 0.8022 0.0147 0.7665 0.0108 0.7788 0.0145 
11131 0.3485 0.2691 0.0148 0.2897 0.0235 0.2800 0.0185 0.3525 0.0168 0.2767 0.0115 
11133 0.1988 0.1321 0.0129 -0.0158 0.0255 0.1739 0.0170 0.1172 0.0137 0.1283 0.0175 
11211 0.8672 0.8556 0.0088 0.9899 0.0175 0.8649 0.0077 0.9495 0.0141 0.8694 0.0072 
11312 0.6300 0.5863 0.0125 0.6233 0.0133 0.5847 0.0175 0.6184 0.0115 0.5929 0.0158 
12111 0.8429 0.8272 0.0107 0.8338 0.0228 0.8440 0.0089 0.8553 0.0137 0.8308 0.0079 
12121 0.7837 0.7587 0.0123 0.7808 0.0196 0.7636 0.0156 0.7778 0.0103 0.7658 0.0149 
12211 0.7951 0.7662 0.0130 0.8238 0.0194 0.7562 0.0140 0.8076 0.0147 0.7694 0.0096 
12222 0.6533 0.6052 0.0111 0.6045 0.0135 0.5951 0.0154 0.6048 0.0107 0.6004 0.0150 
12223 0.4441 0.3693 0.0149 0.2187 0.0255 0.3634 0.0130 0.2919 0.0179 0.3878 0.0116 
13212 0.4704 0.3988 0.0148 0.3349 0.0305 0.4446 0.0180 0.4051 0.0132 0.4209 0.0161 
13311 0.4131 0.3402 0.0119 0.3864 0.0240 0.3352 0.0120 0.4030 0.0173 0.3468 0.0109 
13332 -0.0131 -0.0679 0.0171 -0.0915 0.0221 -0.0981 0.0215 -0.0575 0.0162 -0.057 0.0195 
21111 0.8788 0.8662 0.0088 0.9630 0.0208 0.8814 0.0150 0.9305 0.0162 0.8709 0.0072 
21133 0.1612 0.0851 0.0162 -0.0094 0.0240 0.1145 0.0142 0.0839 0.0152 0.0917 0.0170 
21222 0.6587 0.6104 0.0111 0.6734 0.0240 0.5810 0.0166 0.6293 0.0160 0.6069 0.0095 
21232 0.3382 0.2480 0.0153 0.2350 0.0191 0.1501 0.0175 0.2310 0.0135 0.2443 0.0157 
21312 0.5972 0.5483 0.0129 0.6804 0.0266 0.5523 0.0127 0.6243 0.0182 0.5611 0.0110 
21323 0.3402 0.2569 0.0155 0.2787 0.0274 0.2352 0.0199 0.2751 0.0148 0.2538 0.0119 
22112 0.7129 0.6685 0.0122 0.6449 0.0260 0.7139 0.0187 0.6698 0.0177 0.6782 0.0099 
22121 0.7154 0.6749 0.0112 0.6859 0.0120 0.6336 0.0169 0.6771 0.0104 0.6649 0.0149 
22122 0.6664 0.6198 0.0127 0.5521 0.0222 0.6114 0.0123 0.5647 0.0168 0.6103 0.0108 
22222 0.5979 0.5365 0.0128 0.5710 0.0210 0.5206 0.0162 0.5433 0.0124 0.5383 0.0147 
22233 0.1236 0.0515 0.0153 -0.0763 0.0241 0.0268 0.0156 -0.0159 0.0194 0.0563 0.0133 
22323 0.2804 0.1926 0.0157 0.1663 0.0214 0.1340 0.0185 0.1680 0.0155 0.1962 0.0161 
22331 0.1844 0.1050 0.0130 0.1693 0.0311 -0.0266 0.0238 0.1342 0.0199 0.1088 0.0130 
23232 0.0973 0.0191 0.0163 -0.0207 0.0240 0.0118 0.0170 0.0189 0.0159 0.0287 0.0176 
[20] 
 
23313 0.1569 0.0814 0.0134 -0.0493 0.0293 0.0536 0.0211 0.0192 0.0200 0.0630 0.0121 
23321 0.3331 0.2539 0.0126 0.2549 0.0173 0.1040 0.0203 0.2448 0.0131 0.2449 0.0170 
32211 0.2408 0.1783 0.0160 0.2302 0.0254 0.1576 0.0152 0.2438 0.0187 0.1676 0.0120 
32223 0.0558 -0.0203 0.0158 -0.1042 0.0229 -0.0284 0.0202 -0.0464 0.0201 -0.0199 0.0130 
32232 0.0051 -0.0677 0.0165 -0.048 0.0260 -0.0877 0.0170 -0.0423 0.0167 -0.0457 0.0135 
32313 0.0278 -0.0331 0.0152 -0.0612 0.0208 -0.0545 0.0227 -0.0360 0.0171 -0.0312 0.0166 
32331 -0.0895 -0.1269 0.0169 -0.020 0.0366 -0.2410 0.0260 -0.0580 0.0210 -0.1259 0.0144 
33212 0.0765 0.0097 0.0170 -0.0288 0.0272 0.0190 0.0171 0.0247 0.0154 0.0179 0.0169 
33232 -0.1263 -0.1662 0.0169 -0.2106 0.0248 -0.2128 0.0220 -0.1733 0.0199 -0.1733 0.0147 
33321 -0.0254 -0.0692 0.0144 0.0154 0.0276 -0.1425 0.0234 -0.0039 0.0198 -0.0752 0.0172 
33323 -0.1999 -0.2184 0.0172 -0.2601 0.0276 -0.2311 0.0192 -0.2184 0.0216 -0.2142 0.0153 
33333 -0.3460 -0.3082 0.0121 -0.3426 0.0259 -0.3337 0.0186 -0.3105 0.0186 -0.3242 0.0135 
RMSE 
 
0.057686448 0.102178895 0.088362357 0.06651562 0.055482987 
 
  
[21] 
 
Table 2: Mean utility values for the left out data comparing US only and US/UK using 25 health 
states 
  
US data ONLY 25 US & UK data 
HS Observed Predicted Predicted STD Predicted Predicted STD 
 
Mean Mean STD RESIDUALS Mean STD RESIDUALS 
11122 0.7693 0.8016 0.1152 0.280381944 0.7454 0.1148 0.208188153 
11133 0.1988 0.3322 0.1918 0.695516163 0.3605 0.1876 0.861940299 
11312 0.6300 0.6598 0.1445 0.206228374 0.6577 0.1446 0.191562932 
12121 0.7837 0.6851 0.1150 0.857391304 0.7065 0.1166 0.662092624 
12222 0.6533 0.5488 0.1233 0.847526358 0.5700 0.1265 0.658498024 
13212 0.4704 0.4515 0.1573 0.120152575 0.4664 0.1576 0.025380711 
13332 -0.0131 0.0160 0.1932 0.150621118 0.0439 0.1893 -0.30110935 
21133 0.1612 0.2294 0.1814 0.375964719 0.2658 0.1786 0.585666293 
21232 0.3382 0.2811 0.1329 0.429646351 0.2957 0.1342 0.316691505 
22121 0.7154 0.5675 0.1286 1.15007776 0.5972 0.1315 0.898859316 
22222 0.5979 0.4403 0.1117 1.410922113 0.4756 0.1131 1.081343943 
22323 0.2804 0.0934 0.1209 1.546732837 0.1251 0.1223 1.269828291 
23232 0.0973 0.0053 0.1413 0.651096957 0.0311 0.1365 0.484981685 
23321 0.3331 0.1228 0.1563 1.345489443 0.1120 0.1543 1.432922878 
32313 0.0278 0.0934 0.1551 0.422952934 0.0949 0.1579 0.424952502 
33212 0.0765 0.1089 0.1671 0.193895871 0.1104 0.1641 0.206581353 
33321 -0.0254 -0.0409 0.1651 0.093882495 -0.0615 0.1672 0.215909091 
RMSE 
 
0.105565536 0.099901607 
Mean 
 
  
0.360432769 
  
0.275463735 
Var 
 
  
0.52363791 
  
0.442980006 
 
 
 
